孔德新,天津市特聘教授,天津市重点领域创新团队“分子靶向药物研究创新团队”负责人,天津市高校药学学科领军人才,天津医科大学特聘教授、博士生导师。中国药理学会肿瘤药理专委会副主任委员,中国抗癌协会抗癌药物专委会副主任委员,日本学术振兴会中国同学会第3任会长、中国生化与分子生物学会工业专业分会常委、中国老年学和老年医学学会肿瘤基础及转化研究专家委员会常委、中国生化与分子生物学会海洋专业分会委员等。国家自然科学基金会审专家。曾获日本学术振兴会“卓越外国研究者”项目奖(2012年)、“桥”项目奖(2019年)。主要研究兴趣为PI3K抑制剂等小分子靶向抗癌药物,曾作为核心研究人员将PI3K抑制剂ZSTK474推向临床试验。 近五年主持的国家及省部级项目 (1)国家自然科学基金, 82281340478, 2022 NSFC-JSPS-CAS "转化医学与创新药物研究"论坛, 2022-11 至 2023-12, 12万元 (2)国家自然科学基金, 82073890, 基于STELB抑制同源重组修复的联合用药抗胶质母细胞瘤研究, 2021-01 至 2024-12, 55万元 (3)国家自然科学基金, 82061148017, 新型PI3K抑制剂的纳米递送增强免疫治疗对PIK3CA突变头颈癌疗效的研究, 2020-10-01 至 2023-09-30, 200万元 (4)国家自然科学基金, 81881340655, 精准医疗背景下创新药物的发现与研发, 2018-09-01 至 2018-12-31, 6万元 (5)天津市科技局, 科技重大专项与工程, 17ZXXYSY00050, 抗肿瘤药物靶点发现平台KTC21的建设, 2017-10 至 2020-12, 100万元 近3年代表性论著 (1) Peng Xin; Huang Xin; Lulu Ben Talal; Jia Wenqing; Zhang Shaolu; Cohen Limor; Huang Shengfan; Fan Jindian; Chen Xi; Liu Shanshan; Wang Yongzhe; Wang Kailin; Isoyama Sho; Dan Shingo; Wang Feng; Zhang Zhe; Elkabet Moshe; Kong Dexin; A novel pan-PI3K inhibitor KTC1101 synergizes with anti-PD-1 therapy by targeting tumor suppression and immune activation, Molecular Cancer, 2024, DOI: 10.1186/s12943-024-01978-0 (IF=37.3, Q1) (2) Peng Xin; Wang Yingying; Zhang Shaolu; Tao Zhennan; Dai Yuxiang; Claret Francois X.; Elkabets Moshe; Lin Hou-Wen; Chen Zhe-Sheng; Kong Dexin ; Stellettin B renders glioblastoma vulnerable to poly (ADP-ribose) polymerase inhibitors via suppressing homology-directed repair, Signal Transduction and Targeted Therapy, 2023, 8(1):119. (IF=39.3, Q1) (3) Peng Xin; Zhang Shaolu; Wang Yingying; Zhou Zhicheng; Yu Zixiang; Zhong Zhenxing; Zhang Liang; Chen Zhe-Sheng; Claret Francois X.; Elkabets Moshe; Wang Feng; Sun Fan; Wang Ran; Liang Han; Lin Hou-Wen; Kong Dexin ; Stellettin B Sensitizes Glioblastoma to DNA-Damaging Treatments by Suppressing PI3K-Mediated Homologous Recombination Repair, Advanced Science, 2023, 10(3): 2205529 (IF=15.1, Q1) (4) Peng Xin; Zhang Shaolu; Jiao Wenhui; Zhong Zhenxing; Yang Yuqi; Claret Francois X; Elkabets Moshe; Wang Feng; Wang Ran; Zhong Yuxu; Chen Zhe-Sheng; Kong Dexin ; Hydroxychloroquine synergizes with the PI3K inhibitor BKM120 to exhibit antitumor efficacy independent of autophagy., Journal of Experimental and Clinical Cancer Research, 2021, 40: 374 (IF=11.3, Q1) (5) Zhang Zhe; Hou Lanjiao; Yu Zixiang; Xu Zesha; Li Shurong; Wang Yingying; Liu Hongyan; Zhao Baoquan; Liu Rui; Wang Wei; Du Bo; Zhong Yuxu; Kong Dexin ; Biomimetic Small-Molecule Self Assembly of PI3K inhibitor integrated with immunomodulator to amplify anticancer efficacy, Chemical Engineering Journal, 2022, 433: 133747 (IF=15.1, Q1) (6) Zhang Zhe; Wang Yingying; Ma Qian; Zhang Shaolu; Liu Hongyan; Zhao Baoquan; Liu Rui; Wang Wei; Du Bo; Zhong Yuxu; Kong Dexin ; Biomimetic carrier-free nanoparticle delivers digoxin and doxorubicin to exhibit synergetic antitumor activity in vitro and in vivo, Chemical Engineering Journal, 2021, 406: 126801 (IF=15.1, Q1) |